

National Indications for Publicly funded PET-CT

Effective from 1 March 2024

Type	Code	Criteria
Anal	AN1	Staging of patients with locally advanced (\geq T2 +/or node positive) anal squamous cell carcinoma.
	AN2	Restaging of patients with residual or recurrent anal squamous cell carcinoma where radical therapy is being considered.
Bladder	BL1	Staging of patients with locally advanced or potentially oligometastatic bladder cancer, where other imaging is indeterminate and radical therapy is being considered.
Breast	BR1	Staging of patients with locally advanced or potentially oligometastatic breast carcinoma, where other imaging is indeterminate or non-diagnostic and where radical therapy is being considered (see additional notes in Evidence-based indications for the use of PET-CT in the United Kingdom 2022, Pg13).
Cardiac Sarcoid	CS1	Initial diagnosis or re-evaluation of patients with sarcoidosis with suspected cardiac involvement, where cardiac MRI is indeterminate or not feasible due to ICD.
Colorectal	CR1	Pre-operative evaluation of patients with colorectal carcinoma who are candidates for resection of metastases.
	CR2	Re-staging of patients with colorectal carcinoma and new abnormality on other imaging following definitive treatment
	CR3	Re-staging of patients with rising tumour markers with indeterminate findings on other imaging following definitive treatment for colorectal carcinoma.
	CR4	Re-staging of patients with loco-regionally recurrent colorectal cancer where pelvic exenteration is being considered
Epilepsy	EP1	Evaluation for focal hypometabolism in refractory partial epilepsy.
Germ cell	GE1	Staging of patients with germ cell tumour where curative therapy is being considered.
GIST	GI1	Restaging of patients with recurrent gastrointestinal stromal tumour (GIST) where curative resection is being considered.
Glioma	GL1	FET PET scan to guide biopsy or target delineation for radiotherapy planning in patients with heterogeneous tumours on MR scan.
	GL2	FET PET scan for differentiation of radio necrosis from recurrent glioma in patients treated with radiotherapy.
Graft Infection	GR1	Evaluation of patients with suspected vascular graft, cardiac prosthesis or pacemaker infection where other imaging is indeterminate
Cervical	GY1	Staging of patients with locally advanced ($>$ FIGO Stage 1A) cervical (includes vaginal and vulval) cancer where curative therapy is being considered.
	GY2	Staging of patients with histologically proven, loco-regionally recurrent cervical, vaginal or uterine cancer, where radical therapy is being considered.
	GY4	Restaging of patients with locally advanced cervical, vaginal or vulval cancer 3-6 months post radical treatment with chemoradiotherapy.
Hepatobiliary	HB2	Staging of patients with gallbladder or bile duct cancer which appears localised on other imaging and where radical surgery is being considered.
Head and Neck	HN0	Staging of locally advanced/node positive head and neck cancer.
	HN1	Restaging of head and neck cancers following definitive treatment or for a residual/recurrent mass.
	HN3	Staging of patients with metastatic SCC in head and neck lymph nodes from an unknown primary with indeterminate findings on other imaging and where radical therapy is being considered.

Type	Code	Criteria
Lung	LU1	Staging of patients with suspected or proven lung cancer (SCLC or NSCLC) where radical treatment is being considered.
	LU2	Evaluation of a pulmonary nodule, minimum diameter of at least 8 mm, where the risk of malignancy is moderate or high, in line with international guidance (reference BTS and Fleischner).
Lymphoma	LYM1	Staging of patients with Hodgkin's Disease and restaging after 2-4 cycles of chemotherapy to inform management options.
	LYM2	Staging of patients with early stage Non Hodgkin's lymphoma to guide indication for radiation and appropriate treatment fields.
	LYM3	Initial staging and restaging at the end of treatment PET CT for High Grade Non-Hodgkin's Lymphoma.
	LYM4	Restaging of patients with residual mass in Hodgkin's and Non Hodgkin's lymphoma following definitive treatment.
	LYM5	Evaluation of response to salvage chemotherapy in patients who are candidates for stem cell transplantation.
	LYM6	Suspected transformation to high grade lymphoma in patients with either SLL/CLL or low grade NHL to guide biopsy site
	LYM7	Restaging of patients with low grade lymphoma at the end of treatment to guide indication for maintenance Rituximab therapy.
Myeloma	MY1	Staging of patients with non-secretory, oligosecretory or extramedullary myeloma, or solitary plasmocytoma, where other imaging is non-diagnostic or indeterminate.
Neuroendocrine	NE1	68Ga-DOTATATE for perioperative staging of patients with neuroendocrine tumour.
	NE2	68Ga-DOTATATE and/or 18F-FDG PET for assessment of patients with neuroendocrine tumours for suitability for PRRT or response to PRRT
Oesophagus	OE1	Staging of patients with oesophageal and gastro-oesophageal junction cancer where radical treatment is being considered.
	OE2	Restaging of patients with oesophageal and gastro-oesophageal junction cancer with suspected recurrence where radical treatment is being considered.
Ovarian	OV1	Restaging of patients with recurrent ovarian and fallopian tube carcinoma where cytoreductive/ curative surgery is being considered.
Pancreas	PANC1	Staging of patients with pancreatic cancer where radical surgery is being considered.
Prostate	PROS1	PSMA PET-CT to be used for initial staging of patients with high-risk prostate cancer (PSA>20, Gleason ≥8, T3a) that are otherwise suitable for locoregional therapy with curative intent.
	PROS2	PSMA PET-CT to be used for restaging of patients with biochemical recurrence (PSA>0.5 post-prostatectomy or 2 above nadir post radical radiotherapy) that are otherwise suitable for further locoregional therapy. Any single patient will only have a maximum of two restaging PSMA PET-CTs per lifetime.
Pyrexia of unknown origin	PU1	Investigation of sustained pyrexia despite antibiotics for >3 weeks where all other investigations have been exhausted and the scan is recommended by an infectious diseases or general medicine consultant
Sarcoma	SA1	Staging of patients with localised, intermediate or high grade sarcoma, where radical therapy is being considered.
	SA2	Re-staging of residual masses in patients with Ewing's sarcoma or rhabdomyosarcoma
Skin	SK1	Staging or restaging of locally advanced or metastatic melanoma for patients who are suitable for treatment with curative intent
	SK2	Staging prior to radical therapy for patients with biopsy proven Merkel cell carcinoma.
	SK3	Staging or restaging of locally advanced cutaneous Squamous cell carcinoma for patients who are otherwise suitable for locoregional therapy with curative intent
Testicular cancer	TE1	Restaging of residual masses in patients with testicular cancer post-definitive treatment
Thyroid	TH1	Assessment of patients with suspected, recurrent thyroid carcinoma based on elevated thyroglobulin where other imaging is negative or indeterminate